Ms Mamuszka is a senior executive in the Cambridge, MA biotech community, with extensive experience in both drug and diagnostic development, validation, and commercialization. With more than 20 years of experience in healthcare from the bench to the business side, Ms Mamuszka believes that diagnostics are the key to Precision Medicine. Her thorough command of cutting-edge science compliments her business acumen when evaluating the complex diagnostics deals that shape this industry. She is a well-respected voice for diagnostics in the industry, and a natural choice to bring change to this field. Prior to founding Alva10, Ms Mamuszka was Vice President of Business Development at Exosome Diagnostics, where she led some of the earliest deals in the liquid biopsy diagnostic space. Earlier in her career, she was Global Director for Pharma Services at Exiqon A/S (now QIAGEN), and worked on the NDA for Bortezmib (Velcade) at Millennium Pharmaceuticals (now Takeda). Ms Mamuszka writes a column for the Journal of Precision Medicine on the increasing value of diagnostics in our healthcare system. She is a competitive marathon runner, and earned degrees from Harvard and the University of Maryland, College Park.
1:45 PM - 2:45 PM
Wednesday, June 5
Payers are evaluating provider and reimbursement policies, seeking value in precision health. This…